AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 293 min read$CORT

Maduck Sean sold $3.6M of CORT

Maduck Sean (See Remarks) sold 54,575 shares of CORCEPT THERAPEUTICS INC (CORT) at $65.37 ($3.57M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published May 29, 2026, 10:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider behavior but does not introduce new company fundamentals (no earnings, trial results, or guidance changes).

02

Market read

Potential short-term sentiment drag from insider selling, but interpretive weight is reduced by the 10b5-1 pre-arrangement.

03

What to watch

Traders should consider the broader pattern of prior Form 4 activity and total insider ownership changes, not a single transaction.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-05-29; reflects sale dated 2026-05-27.

Background

SEC Form 4 insider transaction disclosure for Corcept Therapeutics; sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics officer Maduck Sean sold 54,575 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Modest, short-lived negative bias possible; no clear directional catalyst beyond sentiment.

Evidence & confidence

The filing is a routine insider transaction and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Limited read-through to biotech/therapeutics peers; this is company-specific insider activity without new clinical/regulatory facts.

Regional

No clear regional spillover; US-listed issuer only.

Global

Low—no deal, trial, or regulatory development reported.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations; price impact may fade quickly.

Key entities

  • officer
    Maduck Sean

    Officer of Corcept Therapeutics who sold shares via an open-market transaction under a 10b5-1 plan.

  • issuer
    Corcept Therapeutics Inc

    US-listed company (CORT) whose insider sale is disclosed in the filing.

Read at source← All news

Related articles

AUG 6
$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 31
$CORTMed

Corcept Therapeutics Q2 Earnings Call Highlights

Vieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI's U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff.

yahoo.com6 min
JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 30
$METAMed

Futures Rise As Oil Drops, Bond Selling Slows, Meta Tumbles And Microsoft Soars

US stock index futures rose in premarket after a prior selloff tied to Fed-related concerns. Microsoft shares jumped about 9% after cloud growth accelerated, while Meta fell about 8% after revenue guidance disappointed and free cash flow was weak. Bond selling slowed and 30-year yields hit a two-decade high near 5.22%. Several other earnings moves were reported, including MO, CVNA, CMG, and QCOM.

zerohedge.com7 min